SNDX News and Press, Syndax Pharmaceuticals Inc. From 12/08/25

– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts – – Retrospective review shows revumenib was well tol...

2025-12-04 08:08:16 ET Overview Encouraged by my recent successful pick of Nuvation Bio, I went back to the FDA’s latest list for approved novel drugs to search for similar small-cap biotech opportunities. There I found Kura Oncology ( KURA ), which commands a mar...

2025-12-02 18:36:47 ET Last month , I reiterated Kura Oncology (NASDAQ: KURA ) as a Strong Buy ahead of FDA approval of Ziftomenib (trade name Komzifti) for the treatment of relapsed/refractory (R/R) NPM1-mutated acute myeloid leukemia (AML). The investment thesis for Kura i...

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 8 th Annual Everc...

2025-11-29 22:08:35 ET Thesis For 3Q25, Syndax Pharmaceuticals ( SNDX ) posted a GAAP EPS loss of –$0.70, which beat estimates by $0.04. Revenue came in at roughly $45.9 million, missing expectations slightly by $2.07 million despite a decent 267% year-over-year incre...

2025-11-10 14:01:39 ET Syndax Pharmaceuticals, Inc. (SNDX) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST... Read the full article on Seeking Alpha For further details see: Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference...

2025-11-05 11:57:38 ET Shares of Syndax Pharmaceuticals, Inc. ( SNDX ) are slightly in the green since my August article provided an overview of the company's two drug launches in AML and chronic GVHD.... Read the full article on Seeking Alpha For further det...

2025-11-03 21:07:37 ET More on Syndax Pharmaceuticals Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call Transcript Syndax Expands Revuforj Approval, Buy Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mut...

2025-11-03 21:06:23 ET Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST... Read the full article on Seeking Alpha For further details see: Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call Transcript

2025-11-03 16:04:10 ET More on Syndax Pharmaceuticals Syndax Expands Revuforj Approval, Buy Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript Syndax Pharmaceuticals, Inc. (...